All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
On Thursday 14 February 2019, a session on the use of chimeric antigen receptor-modified T (CAR T) cell therapy took place at the 1st European CAR T Cell Meeting, Paris, France. A talk was presented by Marie José Kersten, Department of Haematology, Academic Medical Center, Amsterdam, Netherlands, on when to use CAR T in lymphoma.
Professor Kersten began her talk by outlining the current treatment landscape of diffuse large B-cell lymphoma (DLBCL):
Then Professor Kersten continued her presentation by introducing the SCHOLAR-1 analysis by Michael Crump, from the Canadian Cancer Trials Group at Queen’s University, Kingston, Ontario, Canada, and colleagues. SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from two large randomized trials and two academic databases:
The SCHOLAR-1 analysis demonstrated consistent poor outcomes for patients with refractory non-Hodgkin lymphoma (NHL), and showed that effective treatments for refractory NHL represents a significant unmet need.
Professor Kersten then summarized how the treatment of B-cell malignancies has evolved in recent years and highlighted that adoptive immunotherapy with CAR T cells is a rapidly growing therapeutic approach to treating patients with B-cell malignancies.
Professor Kersten concluded her talk by stating that CAR T cell therapy in DLBCL has been shown to lead to durable remissions. Currently, there is no curative treatment option for this patient population and, thus, it is encouraging that real-world experiences showed that CAR T therapy is a feasible treatment option for patients with DLBCL.
Implementation of CAR T-cell therapy in the real world - A round table discussion
The Lymphoma Hub is pleased to report a summary of real-world experiences of chimeric antigen receptor (CAR) T-cell implementation as discussed at the 2nd European CAR...
SOHO 2019 | Will CAR T-cell therapy become standard of care for patients with R/R DLBCL?
At SOHO 2019, Dr David G. Maloney from Fred Hutchinson Cancer Research Center spoke to us about the possibility of CAR T-cell therapy becoming a standard of care...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox